We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ATOS

Price
0.63
Stock movement down
-0.01 (-1.80%)
Company name
Atossa Genetics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
79.82M
Ent value
10.85M
Price/Sales
4434.49
Price/Book
1.08
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-38.63%
1 year return
-64.15%
3 year return
-18.68%
5 year return
-16.68%
10 year return
-46.18%
Last updated: 2025-04-14

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ATOS does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4434.49
Price to Book1.08
EV to Sales602.82

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count125.80M
EPS (TTM)-0.21
FCF per share (TTM)-0.16

Income statement

Loading...
Income statement data
Revenue (TTM)18.00K
Gross profit (TTM)-23.00K
Operating income (TTM)-29.49M
Net income (TTM)-26.91M
EPS (TTM)-0.21
EPS (1y forward)-0.25

Margins

Loading...
Margins data
Gross margin (TTM)-127.78%
Operating margin (TTM)-163827.78%
Profit margin (TTM)-149505.56%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash74.77M
Net receivables0.00
Total current assets77.11M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets79.48M
Accounts payable1.56M
Short/Current long term debt0.00
Total current liabilities5.80M
Total liabilities5.80M
Shareholder's equity73.68M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-19.55M
Capital expenditures (TTM)19.00K
Free cash flow (TTM)-19.57M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-36.52%
Return on Assets-33.86%
Return on Invested Capital-36.52%
Cash Return on Invested Capital-26.56%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.65
Daily high0.67
Daily low0.62
Daily Volume524K
All-time high2226.60
1y analyst estimate6.00
Beta1.23
EPS (TTM)-0.21
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ATOSS&P500
Current price drop from All-time high-99.97%-12.04%
Highest price drop-99.98%-56.47%
Date of highest drop28 Dec 20229 Mar 2009
Avg drop from high-93.05%-11.07%
Avg time to new high195 days12 days
Max time to new high3038 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ATOS (Atossa Genetics Inc) company logo
Marketcap
79.82M
Marketcap category
Small-cap
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Employees
12
Investor relations
-
SEC filings
CEO
Steven C. Quay
Country
USA
City
Seattle
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...